Corporate
Description
  • Value proposition

    Teva Pharmaceuticals has been developing and producing medicines to help improve people’s lives for more than a century. We are committed to being a global leader in generic and specialty medicines with a portfolio of 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day. They are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.

    Please note that adverse effects for any of our products should be reported to: Safety.AE@teva.co.il

    Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here:
    http://www.tevapharm.com/contact_us/

    generic medicines, specialty medicines, CNS, active pharmaceutical ingredients, respiratory, biosimilars, biologics, pain care, migraine, and oncology

Entity interactions BETA
Entity TypeTweets Articles
Nudge Global Impact Challenge Nudge Global Impact Challenge
Professional Training and Coaching
Other

31 Jul 2024


Wieland Group Wieland Group
Industrial Machinery Manufacturing
Other

30 Jun 2024


Investor Access Investor Access
Other

30 Apr 2024


Coopération Santé Coopération Santé
healthtech
Other

12 Jun 2024


Nanoform Nanoform
biotech, deeptech, Pharmaceutical Manufacturing
Other

11 Jun 2024


PharmaVie PharmaVie
biotech, deeptech, Pharmaceutical Manufacturing
Other

27 May 2024


Market Logic Software Market Logic Software
martech, Software Development
Other

11 Jun 2024


Hack Belgium Labs Hack Belgium Labs
Events Services, it services
Other

13 May 2024


The European House-Ambrosetti The European House-Ambrosetti
Business Consulting and Services
Other

22 May 2024


DTx Conference Series DTx Conference Series
Other

31 Mar 2024


Radars
Loading...